Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to assess whether treatment adaptation based on a very
early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced
stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing
regimens.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC